FOR SLOW INTRAVENOUS ADMINISTRATION

Rx Only

DESCRIPTION

Methylene Blue Injection, USP is a sterile solution of Phenothiazin-5-ium, 3, 7-bis (dimethylamino)-, chloride, trihydrate. Each mL contains methylene blue, 10 mg in water for injection q.s. pH adjusted with hydrochloric acid and/or sodium hydroxide when necessary.

The structural formula is:

The molecular formula is:

C16H18ClN3S • 3H2O                                                      MW 373.90

CLINICAL PHARMACOLOGY

Methylene blue will produce two opposite actions on hemoglobin. Low concentrations will convert methemoglobin to hemoglobin. High concentrations convert the ferrous iron of reduced hemoglobin to ferric iron which results in the formation of methemoglobin.

Methylene blue is metabolized in the body to leukomethylene blue which is excreted primarily in the urine..  Some unchanged drug is also excreted in the urine.(1)

INDICATIONS AND USAGE

Drug-induced methemoglobinemia.

CONTRAINDICATIONS

Methylene blue can cause fetal harm when administered to a pregnant woman.  An association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions and other adverse effects in the neonate. (2,3)  Methylene blue is contraindicated in women who are or may become pregnant.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Intraspinal and subcutaneous injections are contraindicated.

Methylene blue is contraindicated in patients with a known hypersensitivity to the drug.

WARNINGS

Methylene blue should not be given by subcutaneous or intrathecal injection.

Methylene blue is a potent monoamine oxidase inhibitor:  Methylene blue has been demonstrated to be a potent monoamine oxidase inhibitor (MAOI) and may cause potentially fatal serotonin toxicity (serotonin syndrome) when combined with serotonin reuptake inhibitors (SRIs).(4) (See DRUG INTERACTIONS.) Serotonin toxicity is characterized by development of neuromuscular hyperactivity (tremor, clonus, myoclonus and hyperreflexia, and, in the advanced stage, pyramidal rigidity); autonomic hyperactivity (diaphoresis, fever, tachycardia, tachypnoea, and mydriasis); and altered mental status (agitation, excitement, and in the advanced stage, confusion). If methylene blue is judged to be indicated, SRIs must be ceased, prior to treatment/procedure/surgery.

PRECAUTIONS

DOSAGE AND ADMINISTRATION

0.1 to 0.2 mL per kg body weight (0.045 to 0.09 mL per pound body weight). Inject methylene blue intravenously very slowly over a period of several minutes.

Methylene blue must be injected intravenously very slowly over a period of several minutes to prevent local high concentration of the compound from producing additional methemoglobin.  Do not exceed recommended dosage.

Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).

HOW SUPPLIED

NDC 0517-0301-10	10 mg/mL	1 mL Single Dose Vial packed in a box of 10.
NDC 0517-0310-10	10 mg/mL	10 mL Single Dose Vial packed in a box of 10.
NDC 0517-0372-71	10 mg/mL	1 mL Ampule packed in a box of 25.
NDC 0517-0373-70	10 mg/mL	10 mL Ampule packed in a box of 25.

REFERENCES

1. DiSanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs II: methylene blue – absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci. 1972;61:1086-1090
2. Cragan JD. Teratogen update: methylene blue. Teratology. 1999;60:42-48.
3. Kidd SA, Lancaster PA, Anderson JC, Boogert A, Fisher CC, Robertson R et al. Fetal death after exposure to methylene blue dye during mid-trimester amniocentesis in twin pregnancy. Prenat Diagn. 1996;16:39-47.
4. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAOA) confirms a theoretical prediction. Br J Pharmacol. 2007;152:946-51.
5. Beutler E. G6PD Deficiency. Blood. 1994;84:3613-3636
6. Youngster I. Arcavi L. Schechmaster R. Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf. 2010;33:713-726

IN0372

Rev. 3/11

MG# 14080

AMERICAN
REGENT, INC.
SHIRLEY, NY 11967

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPLE DISPLAY PANEL –  1 mL Container

NDC 0517-0301-10

METHYLENE BLUE INJECTION, USP

1% (10 mg/mL)

1 mL SINGLE DOSE VIAL

FOR SLOW IV ADMINISTRATION

Rx Only

AMERICAN REGENT, INC.

SHIRLEY, NY11967

PRINCIPLE DISPLAY PANEL –  10 mL Container

NDC 0517-0310-10

METHYLENE BLUE INJECTION, USP

1% (10 mg/mL)

10 mL SINGLE DOSE VIAL

FOR SLOW INTRAVENOUS ADMINISTRATION

Rx Only

AMERICAN REGENT, INC.

SHIRLEY, NY 11967

PRINCIPLE DISPLAY PANEL –  1 mL Container

NDC 0517-0372-71

METHYLENE BLUE INJECTION, USP

1% (10 mg/mL)

1 mL AMPULE

FOR SLOW INTRAVENOUS ADMINISTRATION

Rx Only

Store at 20° to 25°C (68° to 77°F) (See USP Controlled Room Temperature).

AMERICAN REGENT, INC.

SHIRLEY, NY 11967

Rev. 11/05

PRINCIPLE DISPLAY PANEL –  10 mL Container

NDC 0517-0373-70

METHYLENE BLUE INJECTION, USP

1% (10 mg/mL)

10 mL AMPULE

FOR SLOW INTRAVENOUS ADMINISTRATION

Rx Only

AMERICAN

REGENT, INC.

SHIRLEY, NY 11967